Medical Cannabis Clinical Study Commencing with World Leading Epilepsy Physicians Development of Proprietary Epilepsy Formula for MXC Pharmaceuticals
• MGC Pharmaceuticals to commence a clinical study to assess the efficacy of a medicinal cannabis formulation in children and adolescents with treatmentresistant epilepsy
• Study brings together two globally renowned epilepsy experts, Dr David Neubauer and MXC Advisory Board member, Professor Uri Kramer to oversee the clinical test program
• Over 65 volunteers already recruited to the 6-week study, with a large pool of potential volunteers that have expressed an interest in participating
• Results from the study will be instrumental in the Company’s development of its own proprietary pharmaceutical grade product for epilepsy treatments
• Potential for future clinical studies globally to use Company’s own proprietary formula and dosage
• The registration and sale of a pharmaceutical product for the treatment of epilepsy presents a significant commercial opportunity
- Forums
- ASX - By Stock
- Ann: Medical Cannabis Clinical Study Commencing
Medical Cannabis Clinical Study Commencing with World Leading...
-
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RGT (ASX) to my watchlist
|
|||||
Last
42.0¢ |
Change
0.165(64.7%) |
Mkt cap ! $20.33M |
Open | High | Low | Value | Volume |
28.0¢ | 42.0¢ | 28.0¢ | $38.62K | 100.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.0¢ | 9051 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | 0.305 |
1 | 208 | 0.275 |
1 | 10000 | 0.270 |
4 | 42000 | 0.250 |
1 | 10000 | 0.245 |
Price($) | Vol. | No. |
---|---|---|
0.490 | 9051 | 1 |
0.500 | 4603 | 3 |
0.530 | 8746 | 1 |
0.540 | 600 | 1 |
0.000 | 0 | 0 |
Last trade - 15.59pm 21/08/2024 (20 minute delay) ? |
Featured News
RGT (ASX) Chart |